Broker Meets Biotech September 2017 Dr. Rosalind Wilson CEO - PowerPoint PPT Presentation

Broker Meets Biotech September 2017 Dr. Rosalind Wilson CEO

Disclaimer • The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares in any jurisdiction. • No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification. • This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Factor Therapeutics Limited, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements. • There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The photographs of clinical subjects used in this presentation are illustrative of medical conditions associated with potential applications of VF-001. • Actual clinical results may vary from those shown. 2

$0.060 Market Overview (As of September 5, 2017) $0.035 (Placement) October 7, 2016: FTT share price (March 18, 2017) rises above $0.06 first time since 1,800,000 0.10 August 3, 2015 Mkt. Cap. A$45.26m 1,600,000 0.08 1,400,000 (As of September 5, 2017) 1,200,000 0.06 1,000,000 800,000 0.04 600,000 Advanced 400,000 Focus 0.02 wound care 200,000 0 0 Clinical Phase II US 25 Aug 16 21 Feb 17 20 Aug 17 Stage Pivotal EU Volume Close $ Issued 5% 730,042,783 Shares Substantial % Issued Capital Insitutional shareholders Shareholders Options 9.5m Allan Gray 13.3% Current Private Investors Investment AUD ~$10m Cash Management Symbol FTT Acorn Capital 8.6% Corporate Stakeholders and Exchange Employees Fidelity Investment 7.7% 41% 54% Research Morgans and Management coverage Taylor Collison 3

Our technology moves a wound toward a more normalised healing process by combining elements of two naturally-occurring substances Our Technology: Targeting Growth Factors to the Vitronectin Wound • Binds to collagen in the wound bed • Provides a scaffold for skin cells to attach and move into the area to begin the healing process Growth Factor (IGF-1) • Signal to stimulate skin cells to move into the wound and multiply 4

Robust Pipeline PC Ph1 Ph2 Ph3 VENOUS LEG ULCER Preparing for End Of Phase 2 meeting (US) VF001 (lead) and return to CE Mark process (EU) DIABETIC FOOT ULCER Engaged with potential clinical collaborators IND package available OCULAR (PCED 1 ) PCED is an orphan indication Potential for rapid transition into clinical development NEW OPPORTUNITIES Monash collaboration in Harlequin Ichthyosis Other orphan indications 5 1. Persistent corneal epithelial defect

What is a Venous Irregular blood Leg Ulcer? flow Dilated vein Warped valve Valve A Venous Leg Ulcer (VLU) is a wound between Thin wall the knee and ankle that is slow to heal because of Regular of vein blood flow problems with blood flow in the veins Skin protruding Risk factors for VLU include • Previous blood clot in the leg (DVT) • Varicose veins • Obesity • Poor mobility e.g. age, arthritis, surgery 6

The Silent Epidemic of VLU – Major Commercial Opportunity 7

A Potential Game-Changer Least severe (Margolis 0) • VF001 is targeted to help patients whose Compression bandages & ulcers do not heal with standard treatment dressings • Little cost-benefit for more expensive &/or 69% invasive treatments 25% Moderate severity • VF001 is a cost-effective treatment that can 6% (Margolis 1) be used in the community setting – a Unmet clinical need potential game changer Low competition Most severe (Margolis 2) Expensive (grafts, cell therapies) FTT’s TARGET MARKET 8

Typically some other Harder Margolis issue (i.e. Prior clinical data 1 and 2 infection) Margolis 0 supports Phase 2 trial 100% 80% design 60% 40% Wound Healing 20% 0% • Early clinical trial – the VitroCARD study - -20% conducted in 2012 -40% Margolis 1 • Wound size was significantly reduced after -60% 12 weeks of treatment -80% -100% FTT’s TARGET MARKET 9

All patients receive standard care 1 during screening, treatment and follow-up VF00102 168 patients at 26 planned sites 2 Screening Moderately severe “Margolis 1” ulcers 2 weeks Clinical Trial: Randomised to treatment with Precision Treatment • VF001 - low or high dose 12 weeks • Matching placebo Medicine for Primary endpoint VLUs • Reduction in ulcer size (% area) Follow-up 12 weeks Secondary endpoints • % of patients with complete closure • Time to ulcer closure • Quality of Life • Pain reduction 1. Moisture dressings and compression bandaging 2. 24 sites at 7 th July 10

VF00102 Trial Status • 280 patients pre-screened and 450 patient visits 1 • All sites actively seeking patients – high level of engagement • Enrolment increasing steadily 200 • Pre-screening helping to focus on the population 150 of interest 100 • High patient compliance 50 with only one withdrawal 0 • Still targeting full enrolment this year Actual Screened Actual Randomized Withdrawn April est. Rand April est. Screen 1. At 7 July, 2017 11

VLU Value Inflection Points Near-term catalysts • Recruitment update – early October • Targeting to finish recruitment in Q4 A successful Phase 2 outcome is a major inflection point • Increases potential of early partnering deal • Serves as a second pivotal study for potential CE Mark resubmission • Enables go/no go decision for progression to Phase 3 pivotal studies 12

Experienced Management Team Dr Rosalind Wilson, CEO Mr Nigel Johnson, COO Dr Wilson’s career has spanned a variety of senior leadership and Mr Johnson has broad experience in manufacturing, supply advisory roles, from small, innovation-led businesses, to global chain management, quality, R&D and regulatory affairs. He has biopharma, including strategy and portfolio management roles at been involved in delivering multiple regulated products from a F.Hoffman-LaRoche (Roche Australia, UK and Switzerland), and blank sheet of paper into manufacturing, including leading the Business Manager at NucleusX. clinical translation of five recombinant proteins. Dr Gary Shooter, Director of R&D Ms Saskia Jo, Director of Finance Ms Jo has over 10 years’ commercial experience in finance and Dr Gary Shooter is an experienced Protein Chemist and has a compliance. She has been with the Company since 2011 and in proven track record in the GMP manufacture and characterisation additional to her financial management roles, serves as of protein-based therapeutics and products. Prior to joining the Company Secretary. company, Dr Shooter was a Senior Research Fellow and Leader of the Tissue Repair and Regeneration Program at QUT. Mr Michael Larcom, Director of Quality Mr Anthony Bishop, Project Director Mr Larcom is an experienced Quality Assurance (QA) Mr Bishop gained experience in a wide range of drug development professional in the pharmaceutical and medical device and management roles. He previously worked for Quintiles in industries. He has key skills in pharmaceutical formulation and Australia and Asia in business development and project process development, internal and external audits (FDA, TGA management roles, as well as leading drug development projects and other third party audits), supplier relationship management, at CSL, Chakra Biotech and MerLion Pharmaceuticals. CAPA, validation, quality systems and start up. 13